Business Description
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Fort Worth, Texas. The company focuses on developing therapies for difficult-to-treat cancers by targeting biological pathways that promote tumor growth and resistance. Its lead product candidate, elraglusib, is a small-molecule inhibitor currently in clinical trials for metastatic pancreatic cancer and various pediatric malignancies.
Financial Statements
In thousands, USD
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|
| Selling, General & Administrative Expenses | 12,203 | 6,484 | 3,265 | 3,820 |
| Research & Development Expenses | 10,293 | 18,676 | 21,708 | 16,387 |
| Operating Profit | (22,495) | (25,161) | (24,974) | (20,207) |
| Interest and Investment Income | 288 | 222 | 353 | 27 |
| Interest Expense | (20) | (19) | (44) | (16) |
| Non-Operating Income | — | (2,328) | (80) | 37 |
| Total Non-Operating Income | 267 | (2,125) | 229 | 47 |
| Income Before Provision for Income Taxes | (22,228) | (27,285) | (24,745) | (20,159) |
| Consolidated Net Income | (22,228) | (27,285) | (24,745) | (20,159) |
| Net Income Attributable to Common Shareholders | (22,228) | (27,285) | (24,745) | (20,159) |
| Basic EPS | -1.06 | -3.26 | -17.24 | -16.65 |
| Diluted EPS | -1.06 | -3.26 | -17.24 | -16.65 |
| Basic Weighted Average Shares Outstanding | 21,022 | 8,373 | 1,435 | 1,211 |
| Diluted Weighted Average Shares Outstanding | 21,022 | 8,373 | 1,435 | 1,211 |
| Shares Outstanding | 23,245 | 19,532 | 1,691 | 1,691 |
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|
| Cash and Cash Equivalents | 13,159 | 8,642 | 2,959 | 20,449 |
| Total Cash and Cash Equivalents | 13,159 | 8,642 | 2,959 | 20,449 |
| Other Current Assets | 484 | 566 | 37 | 34 |
| Total Current Assets | 13,643 | 9,208 | 2,996 | 20,483 |
| Other Long-Term Assets | 392 | 111 | — | — |
| Total Assets | 14,036 | 9,318 | 2,996 | 20,483 |
| Accounts Payable | 1,524 | 1,921 | 3,422 | 2,131 |
| Accrued Expenses | 4,156 | 6,810 | 3,499 | 2,214 |
| Other Current Liabilities | 27 | 71 | — | — |
| Total Current Liabilities | 5,707 | 8,803 | 6,921 | 4,345 |
| Other Long-Term Liabilities | 405 | 412 | 1,523 | 1,306 |
| Total Long-Term Liabilities | 405 | 412 | 1,523 | 1,306 |
| Total Liabilities | 6,112 | 9,214 | 8,444 | 5,651 |
| Common Stock | 0 | 0 | 0 | 0 |
| Additional Paid-in Capital | 162,532 | 132,484 | 5,468 | 5,044 |
| Retained Earnings | (154,608) | (132,380) | (105,095) | (80,350) |
| Total Common Shareholders' Equity | 7,924 | 104 | (99,627) | (75,305) |
| Minority Interests and Other | — | — | 94,178 | 90,138 |
| Total Shareholders' Equity | 7,924 | 104 | (5,448) | 14,832 |
| Total Liabilities and Shareholders' Equity | 14,036 | 9,318 | 2,996 | 20,483 |
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|
| Net Income | (22,228) | (27,285) | (24,745) | (20,159) |
| Share-Based Compensation Expense | 6,047 | 1,996 | 424 | 654 |
| Other Adjustments | 20 | 2,347 | 123 | (20) |
| Changes in Accounts Payable | (513) | (1,501) | 1,291 | 586 |
| Changes in Accrued Expenses | (2,726) | 3,241 | 1,285 | 1,171 |
| Changes in Other Operating Activities | 193 | (640) | (3) | (25) |
| Cash from Operating Activities | (19,206) | (21,843) | (21,625) | (17,794) |
| Issuance of Short-Term Debt | — | 200 | — | — |
| Repayments of Short-Term Debt | — | (200) | — | — |
| Net Issuance / (Repayments) of Short-Term Debt | — | 0 | — | — |
| Issuance of Long-Term Debt | — | 5,500 | — | — |
| Net Issuance / (Repayments) of Long-Term Debt | — | 5,500 | — | — |
| Issuance of Common Shares | 24,027 | 23,957 | — | — |
| Net Issuance / (Repurchases) of Common Shares | 24,027 | 23,957 | — | — |
| Issuance of Preferred Shares | — | — | 4,135 | 19,256 |
| Net Issuance / (Repurchases) of Preferred Shares | — | — | 4,135 | 19,256 |
| Other Financing Activities | (303) | (1,931) | — | — |
| Cash from Financing Activities | 23,724 | 27,526 | 4,135 | 19,256 |
| Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash | 4,518 | 5,683 | (17,491) | 1,461 |
Key Metrics & Ratios
| Metric | Value |
|---|---|
| Market Cap | $142M |
| P/E | -5.77x |
| EV/EBITDA | -5.74x |
| Return on Equity | -553.7% |
| Return on Invested Capital | -8943.8% |
| Current Ratio | 2.39x |
Margins
Gross margin
—
Operating margin
—
Net margin
—
Quarterly Trend
| Quarter | Revenue | YoY growth | Operating margin | Operating income |
|---|---|---|---|---|
| Q1 2026 | — | — | — | $-6M |
| Q4 2025 | — | — | — | $-5M |
| Q3 2025 | — | — | — | $-5M |
| Q2 2025 | — | — | — | $-6M |
| Q1 2025 | — | — | — | $-6M |
| Q4 2024 | — | — | — | $-7M |
| Q3 2024 | — | — | — | $-5M |
| Q2 2024 | — | — | — | $-5M |
More on Actuate Therapeutics, Inc.
Figures compiled from public company filings.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.